Samsung Teams Up With US Battery Startup Seeking Pentagon Cash

Samsung SDI will provide $20 million plus engineering support to Forge Nano, a US battery startup building cells for defense and aerospace applications in North Carolina. The deal also includes Samsung buying cells from Forge Nano, helping it avoid tariffs and meet forthcoming US rules aimed at removing Chinese materials from the military supply chain. The transaction gives Forge Nano capital and manufacturing expertise while strengthening Samsung's US supply-chain positioning.

Analysis

This is less a one-off corporate partnership than a signal that defense-battery supply chains are beginning to bifurcate: a premium, compliance-driven domestic lane versus the commoditized global EV lane. The economic value here is not in cell chemistry alone but in certification, traceability, and procurement eligibility, which can create durable pricing power for the firms that get embedded early in DoD/aerospace programs. That tends to favor the closest industrial enablers around factory buildout, quality systems, and test equipment more than headline battery makers.

The second-order winner is likely the broader US onshoring ecosystem: specialty chemicals, dry-room equipment, formation/testing gear, and North Carolina industrial real estate/utilities. If the Pentagon spend path advances, the real constraint becomes qualification time, not capital, so suppliers with existing aerospace/defense documentation can capture disproportionate share before smaller startups scale. Incumbent Asian battery players may also accelerate their own US JV and localization efforts to avoid being trapped in a tariff/regulatory dead zone.

The main risk is timing mismatch: these partnerships can look strategically positive months before they translate into revenue, and startup execution risk is high. A reversal would likely come from procurement delays, export-control friction, or a weaker defense budget cycle that pushes domestic qualification into FY26+ rather than near term. The contrarian point is that the market may overestimate how much this changes near-term battery economics; the value creation is more in option value on future Pentagon demand than in current cash flow.

For public markets, the trade is probably in the picks-and-shovels and industrial localization basket, not in chasing battery beta. If tariffs/regulation tighten further, the relative winners should be US-based manufacturing equipment and facility builders that can monetize multiple customer programs, while foreign cell producers face margin compression from duplicated capex and slower qualification cycles. That creates a medium-term spread trade: long the infrastructure that enables compliance, short the names most exposed to China-linked supply chains without domestic alternates.

Key Decisions for Investors

• Long a US industrial localization basket for 3-6 months: XLI vs. short a China-linked battery/supply-chain proxy basket. Target 8-12% relative outperformance if defense localization remains a priority; stop if Pentagon qualification headlines stall for a quarter.
• Buy LECO / AMAT / TER on pullbacks as indirect picks-and-shovels exposure to cell qualification, testing, and manufacturing ramp. Best risk/reward is a 6-12 month hold: upside comes from multiple domestic battery programs, while downside is limited by existing secular semiconductor/industrial demand.
• For venture/illiquid mandates, back US battery-adjacent infrastructure providers rather than pure cell startups; structure as milestone-based financing or preferred equity to reduce execution risk. Expect 2-3x outcomes only if procurement conversion happens within 18-24 months.
• Watch for a long-dated call spread in an industrial REIT or utilities name with North Carolina exposure if additional plant announcements follow. The catalyst window is 1-2 quarters, with utility load and land absorption as the first measurable indicators.
• Avoid paying up for pure-play battery commercialization until there is evidence of signed defense/aerospace offtake. The current signal is strategic, not yet earnings-accretive, so chase only on confirmed contract awards.